Sra-333
Mild Cognitive Impairment
Helse Stavanger HFPhase 4 / ApprovedActive
BBB
74/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 75/ 100
- Competitive Position
- 73/ 100
Competitive context
98 Active assets in the Mild Cognitive Impairment cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Metformin Fudan University | Phase 4 | BB |
Ginkgo Biloba Dr. Willmar Schwabe GmbH & Co. KG | Phase 4 | BB |
Ginkgo Biloba Extract Hanyang University | Phase 4 | BB |
Methylphenidate St. Jude Children's Research Hospital | Phase 4 | BB |
Duloxetine University of North Texas Health Science Center | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Sra-333 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →